Heraeus Medical received FDA 510(k) marketing clearance and commenced launch of COPAL G+V, the company’s antibiotic-loaded PMMA bone cement with gentamicin and vancomycin to support periprosthetic joint infection (PJI) treatment.
COPAL G+V is a high-viscosity dual antibiotic-loaded bone cement containing the antibiotics 0.5g of gentamicin and 2g of vancomycin per 40g unit. This combination is effective against most pathogens related to PJI, including MRSA/MRSE. COPAL G+V provides a high local antibiotic elution at the surgery site and a low systemic burden for the patient. Since 2012, COPAL G+V has been used successfully in several regions around the world (including Europe and Australia), enabling orthopedic surgeons to provide patients with added protection of the implant during infection management in arthroplasty procedures.
Scott Druhot, Vice President of Marketing and Clinical Education for Heraeus Medical USA, said, “Revisions for PJI are devastating to patients and very costly to healthcare systems. Now that COPAL G+V is launched in the United States, it will be a great addition to our PJI portfolio and reflects our commitment to being an innovator and a leader in infection management.”
Heraeus Medical received FDA 510(k) marketing clearance and commenced launch of COPAL G+V, the company’s antibiotic-loaded PMMA bone cement with gentamicin and vancomycin to support periprosthetic joint infection (PJI) treatment.
COPAL G+V is a high-viscosity dual antibiotic-loaded bone cement containing the antibiotics 0.5g of gentamicin and...
Heraeus Medical received FDA 510(k) marketing clearance and commenced launch of COPAL G+V, the company’s antibiotic-loaded PMMA bone cement with gentamicin and vancomycin to support periprosthetic joint infection (PJI) treatment.
COPAL G+V is a high-viscosity dual antibiotic-loaded bone cement containing the antibiotics 0.5g of gentamicin and 2g of vancomycin per 40g unit. This combination is effective against most pathogens related to PJI, including MRSA/MRSE. COPAL G+V provides a high local antibiotic elution at the surgery site and a low systemic burden for the patient. Since 2012, COPAL G+V has been used successfully in several regions around the world (including Europe and Australia), enabling orthopedic surgeons to provide patients with added protection of the implant during infection management in arthroplasty procedures.
Scott Druhot, Vice President of Marketing and Clinical Education for Heraeus Medical USA, said, “Revisions for PJI are devastating to patients and very costly to healthcare systems. Now that COPAL G+V is launched in the United States, it will be a great addition to our PJI portfolio and reflects our commitment to being an innovator and a leader in infection management.”
Copy to clipboard 
